ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripAnalysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US
ScripPublic biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis
Pink SheetReal-world evidence from expanded access programs and a natural history external control played important roles in recent US FDA decisions on the suitability of the accelerated approval pathway for C